Skip to Content

Bayer AG ADR BAYRY Stock Quote

| Rating as of


Morningstar‘s Stock Analysis BAYRY

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Undervalued Bayer Posts Strong 3Q, Buoyed by Strong Crop Science Pricing and Recent Drug Launches

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

Bayer reported strong third-quarter results ahead of our expectations, but we don’t expect any major changes to our fair value estimate. Strong crop science prices partly supported the outperformance, but we expect increased competition in 2023, which will likely reverse some of Bayer's recent gains. However, the crop science business remains well positioned for growth over the long term, led by innovative new products (such as short-stature corn and next-generation trait protection) that help reinforce the firm’s wide moat.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics BAYRY

Company Profile BAYRY

Business Description

Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins. The firm has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through the acquisition of Monsanto.

Kaiser-Wilhelm-Allee 1
Leverkusen, 51368, Germany
T +49 214301
Industry Drug Manufacturers - General
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Employees 100,753

Related News BAYRY